<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707002</url>
  </required_header>
  <id_info>
    <org_study_id>PEC14513</org_study_id>
    <nct_id>NCT03707002</nct_id>
  </id_info>
  <brief_title>Effect of scFOS on Increase in Stool Frequency in Constipated People</brief_title>
  <acronym>CONSYST</acronym>
  <official_title>Randomized, Placebo-controlled Double Blind Study to Evaluate the Effects of Dietary Supplementation With Short-chain Fructo-oligosaccharides (scFOS) on Nincrease in Stool Frequency in Constipated People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syral</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biofortis Mérieux NutriSciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CreaBio Rhone-Alpes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Syral</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the effects of short-chain fructo-oligosaccharides on the
      frequency and consistency of stools in subjects with functional constipation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, placebo-controlled, double-blind study aims to evaluate the effects of
      short-chain fructo-oligosaccharides on the frequency and consistency of stools in subjects
      with functional constipation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Identical sachets containing 5g of scFOS or placebo (maltodextrins)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in the number of stool per week between week at Baseline and the last week of supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in the stool consistency between Baseline and the end of supplementation, (Bristol Stool Scale 1 = hard to 7 = watery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of Gastrointestinal symptoms</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in the frequency (number of occurrence) and severity (Likert scores from 0= no symptom to 7 =severe symptoms) individual Gastro-Intestinal symptoms (bloating, abdominal pain, flatulence,...) between Baseline and the end of supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>6 weeks</time_frame>
    <description>Changes in anxiety and depression score between Baseline and the end of supplementation, measured by HAD score (Zigmond et al, 1983, from 0 to 21, score above 11 = anxiety or depression related pathology</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>at baseline and at the last visit (after 6 weeks)</time_frame>
    <description>heart rate (bit per minute)</description>
  </other_outcome>
  <other_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>at baseline and at the last visit (after 6 weeks)</time_frame>
    <description>systolic blood pressure (mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>at baseline and at the last visit (after 6 weeks)</time_frame>
    <description>diastolic blood pressure (mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse event</measure>
    <time_frame>6 weeks</time_frame>
    <description>Registration of all adverse events (number and severity of events)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Functional Constipation</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>scFOS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>scFOS consumed at 5g/day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maltodextrin consumed at 5g/day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>scFOS</intervention_name>
    <description>daily intake for 6 weeks</description>
    <arm_group_label>scFOS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>daily intake for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  functional constipation according to ROME III criteria with 3 or less than 3 stools
             per week

          -  BMI between 18 and 32kg/m², limits included

          -  Subjects who do not usually eat high-fibre foods

          -  Subjects who do not usually consume foods siad &quot;reduced in sugars&quot; or &quot;light&quot;

          -  Subjects who do not consume regularly pre- and probiotics in the form of dietary
             supplements

        Exclusion Criteria:

          -  subjects presenting Irritable bowel syndrome

          -  history of chronic GI disorders: crohn disease, ulcerative colitis,....

          -  treatments likely to influence GI sensitivity or motility (laxative, neuroleptics,...)

          -  Antibiotic therapy in progress or in the past 8 weeks

          -  medical history with impact on the study objectives as defined by investigator

          -  known food allergy to one of the compounds of the study product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gendre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioFortis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biofortis SAS</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

